Cancer Research

Pharma company completes Coramsine phase I trial, commences phase II trial

Published in Medical Letter on the CDC and FDA, March 12th, 2006

Solbec Pharmaceuticals (SBP) advised that following the successful completion of Coramsine's phase I cancer clinical trials, the company has proceeded with the commissioning of the Australian phase II trials as outlined below.

The company has selected the principal investigator for its Australian phase II metastatic renal cell carcinoma trial and begun identifying suitable trial sites. The manufacturing and quality agreements for the good manufacturing practices (GMP) production of the clinical trial material are now in place with Patheon U.K. Limited. It is expected that the Australian trials will commence recruitment during Q2 2006.

Solbec is also...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-03-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry